Virtual Library
Start Your Search
Jacek Jassem
Author of
-
+
MS24 - Global Perspectives on Tobacco Control (ID 802)
- Event: WCLC 2018
- Type: Mini Symposium
- Track: Prevention and Tobacco Control
- Presentations: 1
- Moderators:
- Coordinates: 9/26/2018, 10:30 - 12:00, Room 206 BD
-
+
MS24.03 - The Importance of Physician Involvement in Tobacco Control (ID 11503)
11:00 - 11:15 | Presenting Author(s): Jacek Jassem
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.01-81 - Treatment of Superior Sulcus Tumor: A Twelve-Year Single-Center Experience (ID 14144)
16:45 - 18:00 | Author(s): Jacek Jassem
- Abstract
Background
Superior sulcus tumor (SST), also known as Pancoast tumor, occurs in up to 5% of all non-small cell lung cancer patients. Owing to its proximity to vital thoracic structures, SST remains one of the biggest challenges of thoracic surgery. The results of the Southwest Oncology Group Trial 9416, in which SST patients were subjected to induction chemoradiation followed by surgical resection, established a widely accepted standard-of-care. Data on the efficacy of this approach outside of clinical trial setting are scarce. We present long-term outcomes in a large group of patients with SST who underwent surgery with or without preoperative treatment (PT) in a single tertiary referral center.
a9ded1e5ce5d75814730bb4caaf49419 Method
Study group included 76 consecutive patients treated between February 2006 and June 2017. All patients had histologically-proven and radiologically-defined T3-T4 N0-N1 M0 superior sulcus non-small cell lung cancer. Study group included 50 men (66%) and 26 women (34%) with a mean age of 56 years (range, 41-81 years). Squamous cell lung cancer constituted 55% of the population.
4c3880bb027f159e801041b1021e88e8 Result
Fifty-four patients (71%) underwent PT, 44 of whom received radiochemotherapy (58%), 4 radiotherapy (5%) and 6 chemotherapy (8%), and 22 (29%) were managed with surgery alone. All patients selected to PT underwent subsequent pulmonary surgery including lung and chest wall en bloc resection, and complete lymphadenectomy. In the entire group 71 lobectomies (93%), 3 segmentectomies (4%) and 2 pneumonectomies (3%) were performed. Surgery in patients managed with PT included 52 lobar resections (96%) and 2 pneumonectomies (4%). Complete or near complete pathologic response following PT was achieved in 67% of operated patients. In the entire group resection was complete (R0) in 62 patients (82%). Overall 30-day and 90-day mortality in the entire treatment group was 2.6% and 6.6%, respectively. Overall 3-year and 5-year survival probabilities were 44% (95% CI: 32%–56%) and 38% (95% CI: 26%–50%) respectively. A non-significantly higher 3-year survival probability was recorded in patients, who underwent PT compared to those managed with surgery alone (50% vs. 36%, respectively; log-rank p=0.27).
8eea62084ca7e541d918e823422bd82e Conclusion
Real-world treatment outcomes in SST patients amenable to surgery are similar to those obtained in the general population of lung cancer patients. PT may increase long-term survival rate and is associated with low perioperative mortality, which justifies its routine application.
6f8b794f3246b0c1e1780bb4d4d5dc53
